Main menu

Oncolytics kicks off reovirus trial

Oncolytics kicks off reovirus trial

March 23, 2009

Oncolytics will start a U.S. phase II trial on Reolysin (reovirus serotype 3) and chemotherapy for NSCLC. Oncolytics said that Reolysin, in combination with certain chemotherapeutics, results in more efficient and synergistic anti-cancer activity than when each agent is used on its own.

Your name

E-mail

The content of this field is kept private and will not be shown publicly.